Evaluation of NUN-004, a Novel Engineered Ephrin Antagonist, in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis: A Phase I/Ib, Open-Label, Escalating Dose and Extended Access Study
用户1-TqkQKBj1O0
3小时前
13
10
待确认
帖子自动结束时间: 2025-10-14 09:24:03
1. 请及时下载文件确认是否正确, 系统将在 2025-10-16 09:31:53 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1007/s40261-024-01410-x
文献链接: https://link.springer.com/10.1007/s40261-024-01410-x
其他信息:
出版社: Springer Science and Business Media LLC
作者: Michael Gerometta; Robert D. Henderson; Richard Friend; Leanne T. Cooper; Jing Zhao; Andrew W. Boyd; Perry F. Bartlett
全文下载地址: https://link.springer.com/content/pdf/10.1007/s40261-024-01410-x.pdf
